Estrogen replacement in perimenopause-related depression: A preliminary report
Estrogen replacement in perimenopause-related depression: A preliminary report
复制标题
DOI：
10.1067/mob.2000.106004
复制
发表时间：
2000-08-01
影响因子：
9.8
通讯作者：
Rubinow, DR
中科院分区：
文献类型：
--
作者：
Schmidt, PJ;Nieman, L;Rubinow, DR
目的：我们研究了雌激素在治疗抑郁症的围绝经期妇女和没有潮热。研究设计：妇女围绝经期相关的抑郁症随机双盲平行设计，接受17 β-雌二醇或安慰剂3周。随后，在前3周接受雌二醇治疗的女性继续接受雌二醇治疗3周，而接受安慰剂治疗的女性交叉接受雌二醇治疗3周。结果的措施包括标准化的情绪评定量表和视觉模拟量表自我报告instrument.RESULTS：34名女性受试者，16人接受雌二醇第一，18人接受安慰剂第一。服用雌二醇3周后，标准化情绪评定量表评分和视觉模拟量表症状评分（例如悲伤、快感缺失和社交孤立）与基线评分相比显着下降（P < .01），并且显着低于接受安慰剂的女性的评分（P <0.01），后者没有表现出显着改善。潮热的存在和治疗持续时间（3周vs 6周）均不影响结果。在80%的受试者接受雌二醇和22%的那些接受安慰剂。结论：在这项初步研究中，雌二醇替代有效地治疗围绝经期抑郁症独立的有益影响，对血管痉挛症状的全部或部分治疗反应。
OBJECTIVES: We examined the efficacy of estrogen in the treatment of depression in perimenopausal women with and without hot flushes.STUDY DESIGN: Women with perimenopause-related depression were randomized in a double-blind parallel design to receive either 17 beta-estradiol or placebo for 3 weeks. Subsequently, women receiving estradiol during the first 3 weeks continued receiving estradiol for an additional 3 weeks, whereas women who had received placebo crossed over to estradiol for 3 weeks. Outcome measures included standardized mood rating scales and a visual analog scale self-report instrument.RESULTS: Of 34 female subjects, 16 received estradiol first and 18 received placebo first. After 3 weeks of estradiol, standardized mood rating scale scores and visual analog scale symptom scores (eg, sadness, anhedonia, and social isolation) were significantly decreased compared with baseline scores (P < .01) and were significantly lower than scores in women receiving placebo (P < .01), who showed no significant improvement. Neither the presence of hot flushes nor the duration of treatment (3 weeks vs 6 weeks) influenced outcome. A full or partial therapeutic response was seen in 80% of subjects receiving estradiol and 22% of those receiving placebo.CONCLUSION: In this preliminary study estradiol replacement effectively treats perimenopausal depression independent of its salutary effects on vasomotor symptoms.